Exosomes derived from MSCs can ameliorate inflammation after acute ischemia or ischemia–reperfusion injury by modulating anti-inflammatory molecules (IL-4 and IL-10) and pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β), and inhibiting microglia activation (70). This evidence concerns the gene IL4 and ischemia.